A patient suffering from late-stage ovarian cancer has marked a global milestone by being the first to undergo a novel engineered immune cell treatment. This initial Phase 1 clinical study is designed to evaluate how safe and effective the therapy is for ovarian and other difficult-to-manage cancers, providing new possibilities for those who have few medical alternatives.

by shortkt.com✓

8 घंटे पहले